Perspective Therapeutics (Perspective Therapeutics) Interest Expense : $-0.08 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Perspective Therapeutics Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Perspective Therapeutics's interest expense for the three months ended in Dec. 2023 was $ -0.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.08 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Perspective Therapeutics's Operating Income for the three months ended in Dec. 2023 was $ -8.93 Mil. Perspective Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $ -0.02 Mil. Perspective Therapeutics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Perspective Therapeutics Interest Expense Historical Data

The historical data trend for Perspective Therapeutics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Perspective Therapeutics Interest Expense Chart

Perspective Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Dec23

Interest Expense

Get a 7-Day Free Trial

-0.08

Perspective Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-	-0.02	-0.03	-0.01	-0.02

Perspective Therapeutics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.08 Mil.

Perspective Therapeutics (AMEX:CATX) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Perspective Therapeutics's Interest Expense for the three months ended in Dec. 2023 was $-0.02 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-8.93 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $2.46 Mil.

Perspective Therapeutics's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Perspective Therapeutics did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Perspective Therapeutics (Perspective Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Perspective Therapeutics Inc (AMEX:CATX) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

AAJ:Germany

Address

350 Hills Street, Suite 106, Richland, WA, USA, 99354

Website

https://www.perspectivetherapeutics.com

Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company operates two reportable business segments: Brachytherapy and Drug Operations. It is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes.

Executives

Williamson Robert F Iii	director	140 LASALLE AVENUE, PIEDMONT CA 94610
Markus Puhlmann	officer: Chief Medical Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Jonathan Robert Hunt	officer: Chief Financial Officer	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Lori A Woods	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Heidi Henson	director	2173 SALK AVENUE, SUITE 250, PMB#052, CARLSBAD CA 92008
Frank Morich	director	40 GUEST STREET, BOSTON MA 02135
Johan M. Spoor	director, officer: CEO	500 BOYLSTON STREET, SUITE 1600, BOSTON MA 02116
Mark John Austin	officer: Controller/Prin Fin&Acct Offic	350 HILLS ST, STE 106, RICHLAND WA 99354
Philip J Vitale	director	8849 E. CALLE DE LAS BRISAS, SCOTTSDALE AZ 85255
Michael W Mccormick	director	9923 EAST BELL ROAD, STE 130, SCOTTSDALE AZ 85260
William Cavanagh	officer: Vice President	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Alan Hoffmann	director	3030 EAST CACTUS ROAD, SUITE 101, PHOENIX AZ 85032
Michael Krachon	officer: VP of Sales & Marketing	350 HILLS STREET, SUITE 106, RICHLAND WA 99354
Krista Cline	officer: Dir. of Operations, Secretary	350 HILLS STREET, STE 106, RICHLAND WA 99354
Jennifer Streeter	officer: VP of Human Resources	350 HILLS STREET SUITE 106, RICHLAND WA 99354